HVAX Technologies SME IPO Details, Financials, Valuation & Peers
Explore HVAX Technologies IPO details, including IPO dates, financial statements, valuation, peer comparison and more.
Overview
HVAX Technologies Limited, founded in 2010, is a specialized provider of turnkey projects in controlled environment infrastructure and cleanroom solutions. Initially established as an HVAC project contractor, the company has evolved into a comprehensive design-to-delivery solution provider for the pharmaceutical, healthcare, chemical, hospital, and FMCG sectors. HVAX delivers engineering, procurement, and execution services, alongside design, consultancy, and equipment supply. The company's expertise lies in providing end-to-end solutions encompassing design, engineering, procurement, installation, testing, commissioning, and operational support. HVAX has completed over 200 projects across 15 countries, including India, UAE, Kenya, and South Africa. HVAX also offers a range of third-party manufactured products, such as cleanroom panels, doors, air handling units, and building management systems.
Key Points:
- Business Focus:
- HVAX specializes in turnkey projects for controlled environment infrastructure and cleanrooms, primarily for the pharmaceutical, healthcare, chemical, hospital, and FMCG industries.
- Services include design, engineering, procurement, installation, testing, commissioning, and consultancy for cleanroom and HVAC systems.
- Product Offerings: HVAX supplies a variety of third-party manufactured products such as cleanroom wall and ceiling panels, flooring systems, air handling units, chillers, LT/HT electrical panels, and more.
- Global Presence:
- The company has completed over 200 projects across 15 countries, including Algeria, Ethiopia, UAE, Ghana, Kenya, New Zealand, Nigeria, Saudi Arabia, and others.
- End-to-End Solutions:
- HVAX provides end-to-end project solutions, from design and engineering to installation, testing, and operational support, ensuring timely project completion.
- Consultancy Services:
- The company also offers design, engineering, and consultancy services, including GAP analysis, validation, technology transfer, and project feasibility studies, particularly for the pharmaceutical sector.
Objects of the Issue
- Funding the working capital requirements
- General Corporate Purpose
IPO Details
Discover essential information crucial for understanding an IPO, including the Price Band, Fresh Issue, Offer For Sale, Total IPO Size and more. Explore these key details to gain insight into the company's public offering.
| Fields | Details |
|---|---|
| IPO Dates | 27 Sep - 01 Oct 2024 |
| IPO Price Band | ₹435 - ₹458 per share |
| Fresh Issue | 7,32,000 shares |
| Offer For Sale | NIL |
| Total IPO Size | ₹33.53 crore |
| Face Value | ₹10 |
| Listing On | NSE |
IPO Timeline
Explore important dates like IPO opening, closing, listing and others, outlining the journey of the Public Offering. This will help you grasp the entire IPO journey effortlessly.
| Event | Date |
|---|---|
| IPO Opening Date | 27 Sep 2024 |
| IPO Closing Date | 01 Oct 2024 |
| Basis Of Allotment | 03 Oct 2024 |
| Refunds | 04 Oct 2024 |
| Demat Transfer | 04 Oct 2024 |
| IPO Listing Date | 07 Oct 2024 |
Financial Statements
Explore a comprehensive financial data table showcasing key metrics including revenue, expenses, net income, and others. Gain valuable insights about the company's financial performance at a glance, facilitating informed decision-making and strategic planning for subscribing to the IPO.
| Period Ended | 31st March 2021 | 31st March 2022 | 31st March 2023 | 31st March 2024 |
|---|---|---|---|---|
| Total Income | 61.83 | 68.79 | 96.14 | 107.47 |
| Total Expenses | 56.60 | 63.21 | 89.15 | 94.88 |
| Net Profit/Loss | 3.72 | 4.18 | 5.20 | 9.39 |
| NPM (*) | 6.12 | 6.13 | 5.42 | 8.85 |
| Total Assets | 36.87 | 53.87 | 78.26 | 63.66 |
| Total Liabilities | 29.05 | 41.86 | 61.05 | 33.06 |
* NPM represents the net profit margin, calculated as a percentage. All other figures are presented in crore (₹cr)
Valuation
Uncover significant valuation metrics such as EPS (Earnings Per Share), ROE (Return on Equity), ROCE (Return on Capital Employed), D/E Ratio (Debt-to-Equity Ratio), Current Ratio, and EBITDA Margin. These key indicators offer insights into the company's financial standing and performance, aiding in informed investment decisions.
| Period Ended | 31st March 2021 | 31st March 2022 | 31st March 2023 | 31st March 2024 |
|---|---|---|---|---|
| EPS | 20.10 | 22.59 | 28.12 | 47.36 |
| ROE (%) | 54.92 | 42.18 | 35.63 | 39.29 |
| ROCE (%) | 38.63 | 26.91 | 22.20 | 25.17 |
| D/E Ratio | 0.89 | 0.84 | 0.98 | 0.80 |
| Current Ratio | 1.07 | 1.17 | 1.19 | 1.80 |
| EBITDA MARGIN (%) | 8.93 | 10.09 | 8.92 | 13.04 |
* Compiled from DRHP/RHP for valuation purposes.
Peer Comparison
Compare key financial metrics with industry peers to gain valuable insights into the company's performance compared to its competitors.
| Name | Revenue | P/E | EPS | RoNW | NAV |
|---|---|---|---|---|---|
| HVAX Technologies Limited | 106.06 | 9.67 | 47.36 | 30.69 | 149.6 |
| Ahlada Engineers Limited | 259.52 | 10.64 | 10.56 | 9.93 | 106.42 |
* Revenue in (₹cr), RoNW in (%), EPS, NAV in (₹). P/E ratio is based on the highest price from the IPO price band.
Subscription Data from NSE and BSE
| Investor Type | Subscribed |
|---|---|
| Qualified Institutional Buyer (QIB) | 14.02 |
| Non-Institutional Investor (NII/HNI) | 77.92 |
| Retail Individual Investor (RII) | 26.69 |
| Total | 34.16 |
* All figures represent multiples of the subscription. Check subscriptions for other ongoing issues here.
IPO Registrar
KFin Technologies Limited
Phone: +91 40 6716 2222/ 18003094001
Email: einward.ris@kfintech.com
Website: www.kfintech.com
Company Promoters
- NIRBHAYNARAYAN SINGH
- PRAYAGDATT MISHRA
Lead Managers
- Fedex Securities Private Limited
Company Address
HVAX Technologies Limited
601, Lodha Supremus, I-Think Techno Campus, Kanjurmarg (East), Mumbai - 400042, Maharashtra
Phone: 022 4972 5039
Email: compliance@hvax.in
Website: www.hvax.in
FAQs
- What is the issue size of the HVAX Technologies SME IPO?The HVAX Technologies SME IPO has an issue size of ₹33.53 crore. This includes a fresh issue of 7,32,000 shares and an offer for sale (OFS) of NIL.
- What is the price band of the HVAX Technologies IPO?The price band for the HVAX Technologies IPO is ₹435 - ₹458 per share.
- What are the bidding dates for the HVAX Technologies IPO?The HVAX Technologies IPO will open for bidding on 27 Sep 2024 and close on 01 Oct 2024.
- What is the allotment date for the HVAX Technologies IPO?The allotment date for the HVAX Technologies IPO is 03 Oct 2024.
- What is the listing date for the HVAX Technologies IPO?The listing date for the HVAX Technologies IPO is 07 Oct 2024.
- What is the HVAX Technologies IPO grey market premium?The grey market premium (GMP) for the HVAX Technologies IPO is currently at ₹25, with an expected listing gain of approximately 5.46%. Remember, the grey market premium is not an official indicator, but it reflects market perception and demand for the IPO shares.